Oncimmune Holdings plc provided earnings guidance for the year 2024. For the period, the company expects revenue to be approximately £3 million, compared with Fiscal Year 2023 revenue from continuing operations of £1.2 million, a growth rate of 150%. Coming up to the end of H1 Fiscal Year 2024, work to achieve approximately 75% of the forecast Fiscal Year 2024 revenue has been secured, with the majority of samples received or expected imminently allowing lab work to begin and revenue to be recognised in due course.